Celltrion to unveil 2nd-phase test result of Covid-19 cure next week
이 글자크기로 변경됩니다.
(예시) 가장 빠른 뉴스가 있고 다양한 정보, 쌍방향 소통이 숨쉬는 다음뉴스를 만나보세요. 다음뉴스는 국내외 주요이슈와 실시간 속보, 문화생활 및 다양한 분야의 뉴스를 입체적으로 전달하고 있습니다.
According to multiple sources from the pharmaceutical and bio industries on Tuesday, Celltrion has decided to disclose the results of the global clinical second-phase test of its Covid-19 treatment CT-P59 (regdanvimab) at the High 1 New Drug Development Symposia to be hosted by the Pharmaceutical Society of Korea on Jan. 13. It will be the first time for Celltrion to unveil detailed data of CT-P59’s second clinical trial.
Celltrion has already applied for a conditional authorization for the Covid-19 antibody treatment with Korea’s Ministry of Food and Drug Safety after completing its global second-phase trial late last year It had not disclosed the test results upon agreement with the ministry, given public’s excessive attention over a Covid-19 treatment.
An unnamed official from Celltrion said that the antibody treatment – when injected to mild and secondary patients – significantly lowers the ratio of them developing into serious conditions.
The second-phase trial has been carried out on 327 Covid-19 patients including those in Korea, Romania, Spain, and the United States. The drugmaker completed final injections on Nov. 25 and applied for a conditional approval with the food and drug safety ministry on Dec. 29.
Apart from the conditional authorization, Celltrion plans to launch third-phase clinical trial in 10 countries.
Shares of Celltrion were trading 0.58 percent lower at 345,500 won ($317.9) on Tuesday.
Celltrion’s founder and Chairman Seo Jung-jin is intent on seeing through the antibody release before his retirement in March.
Under Seo’s leadership, Celltrion made its name in the 1 trillion won club in 2019 with 1.13 trillion won in revenue, significantly up from 141.1 billion won in 2009. In the first nine months of last year, the drugmaker raised 547.4 billion won in operating profit on sales of 1.36 trillion won and it is poised to become Korea’s largest pharma and bio company in sales, according to Financial Supervisory Service.
The company aims to become one of world’s top 10 pharmaceutical firms by 2030.
[ⓒ Maeil Business Newspaper & mk.co.kr, All rights reserved]
Copyright © 매일경제 & mk.co.kr. 무단 전재, 재배포 및 AI학습 이용 금지
- Korea’s anti-piracy unit arrives at Strait of Hormuz to respond to seized tanker - Pulse by Maeil Business News Korea
- Daewoong’s Phase 3 trial of Covid-19 cure for severely ill patients cleared in Korea - Pulse by Maeil Business News Korea
- Koreans spend record amount on alcohol, tobacco amid pandemic - Pulse by Maeil Business News Korea
- Korean shipyards likely topped global order list in 2020, expect another bumper year - Pulse by Maeil Business News Korea
- Hyundai, Kia keep sale target modest after ending 2020 at 9-year weakest - Pulse by Maeil Business News Korea
- 강경준, 상간남 피소…사랑꾼 이미지 타격 [MK픽] - 스타투데이
- 엔비디아, 시스코처럼 폭락 전철 밟을까
- 하이브 “法 판단 존중…민희진 해임건 찬성 의결권 행사 않을 것”(전문)[공식입장] - MK스포츠
- 이찬원, 이태원 참사에 "노래 못해요" 했다가 봉변 당했다 - 스타투데이
- 양희은·양희경 자매, 오늘(4일) 모친상 - 스타투데이